Harnessing the Prokaryotic Adaptive Immune System as a Eukaryotic Antiviral Defense

Price, A.A et al.  Trends in Microbiology (2016) http://www.ncbi.nlm.nih.gov/pubmed/26852268

Viral diseases result in acute and chronic illnesses, often with limited treatment options.  CRISPR/Cas9 technology could be used as to treat chronic viral diseases such as HIV/AIDS, Hepatitis B, and HPV. However, the research into these applications is still in its infancy.  This review highlights the potential for CRISPR/Cas9 technology to be adapted for use as a eukaryotic antiviral therapy as well as the areas where more research is needed.

Author: Advanced Analytical

Advanced Analytical Technologies, Inc. (AATI) simplifies complex genomics workflows to accelerate research and discovery in pharmaceuticals, life science, biofuels, biotechnology and healthcare.

Leave a Reply